Pharmaceutical Executive
May 01, 2011
Issue PDF
0
0
Sizing Up For Success
May 01, 2011
Sponsored Content
0
0
Rising income per capita and a budding consumer health consciousness are fueling a CAGR of 9.5%, giving investors plenty of room to expand market penetration
May 01, 2011
Features
0
0
Cloud computing is slowly but surely becoming the IT platform of choice for the industry. Pharm Exec looks at how it now affects nearly every aspect of the pharma business.
May 01, 2011
Columns
0
0
According to Eli Lilly, managing alliances requires more than good people skills
May 01, 2011
Columns
0
0
The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance
May 01, 2011
Columns
0
0
To what extent are generics companies obligated by law to request labeling changes with FDA?
May 01, 2011
Columns
0
0
Online sentiment analysis monitoring can help biopharma resource managers make crucial decisions
May 01, 2011
Columns
0
0
Why is building a successful marketing program so difficult? It should be simple, if your product is worth marketing.
May 01, 2011
Features
0
0
Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies.
May 01, 2011
Columns
0
0
The sleek, portable iPad, coupled with customized apps, gives sales reps a leg up
May 01, 2011
Sponsored Content
0
0
Considering Big Pharma's trade objectives, the success of regional regulatory harmonization is not insignificant
May 01, 2011
Columns
0
0
Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies
May 01, 2011
Columns
0
0
The EU is largely powerless when it comes to policies over pricing and reimbursement
May 01, 2011
Columns
0
0
A factory tour to examine Merck's automated robots-and the human minds that inspire them
May 01, 2011
From the Editor
0
0
What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
May 01, 2011
Features
0
0
The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control